Roche Czech Republic - Indebtedness

Net Debt/EBITDA & Net Debt/Equity
Pharmaceutical | Czech Republic | March 19, 2018
$2.99
Excel Sheet

Roche Czech Republic's net debt reached CZK 660 mil and accounted for 0.557 of equity at the end of 2015. The ratio is up 16.7% when compared to the previous year.

Historically, the firm’s net debt to equity reached an all time high of 1.13 in 2004 and an all time low of -0.100 in 2003.

When compared to EBITDA, net debt amounted to 3.15x at the end of the year. The ratio reached an all time high of 4.29 in 2007 and an all time low of -0.170 in 2003.

As far as Roche Czech Republic's peers are concerned, Bayer Czech Republic posted net debt to equity of 0.608x and 0.890x when compared to EBITDA at the end of 2015. Amgen Czech Republic ended the year 2015 with a net debt at 0.387x of equity and 1.53x when compared to its EBITDA while Amgen Czech Republic had net debt at 0.387x of equity and 1.53x to EBITDA at the end of the year.

You can see all the company’s data at Roche Czech Republic Profile, or you can download a report on the company in the report section.